Products with Anti-rheumatism-arthritis bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5408 | Hecogenin |
| Hecogenin, a steroid saponin isolated from Agave sisalana, is a potent and highly selective inhibitor of UGT1A4 with an IC50 value of 1.5 μM. Hecogenin has anti-cancer, antiproliferative,antioxidant and anti-inflammatory effects, it can protect gastro by K⁺(ATP) channels opening and the COX-2/PG pathway. Hecogenin has inhibition of human rheumatoid arthritis synovial cell survival, the effect is associated with increased apoptosis, p38 mitogen-activated protein kinase activity and upregulation of cyclooxygenase-2. | |
| BCN5742 | Mollugin |
| Mollugin is a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Mollugin has anticancer efficacy, can modulate the HER2, HO-1, Nrf2 , and NF- κB pathways. | |
| BCN5856 | Esculentic acid |
| 1. Esculentic acid has anti-inflammatory effect. 2. Esculentic acid has protective effects against LPS-induced endotoxic shock may be mediated, at least in part, by regulation the release of inflammatory cytokines and mediators, and protein expression of COX-2 in mice. | |
| BCN5905 | 6,7-Dihydroxycoumarin |
| 6,7-Dihydroxycoumarin(Esculetin) has various biological and pharmaceutical properties including anti-edema, anti-inflammatory, anti-tumour, hepatoprotective, anti-osteoarthritis and anti-rheumatoid arthritis effects. It inhibits lipoxygenases (LOs), p42/44 MAPK activation, PI3-kinase activation, as well as NF-kappaB and AP-1 activation, it exhibits competitive inhibition against the oxidation of 3-(3,4-dihydroxyphenyl)- alanine by mushroom, the IC50 value of is 43 microM. | |
| BCN6265 | Sinomenine |
| Sinomenine shows neuroprotective, anti- rheumatoid arthritis, anti-inflammatory and immunosuppressive effects, it can attenuate 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice and the therapeutic mechanism may be related to the reduction of up-regulated colonic TNF-alpha and IFN-gamma production caused by TNBS. Sinomenine also provides a novel therapy to treat ICH induced brain injury. Sinomenine can prevent galactosamine (GalN)/lipopolysaccharide (LPS) -treated hepatic failure by suppressing TNF production and/or reactive oxygen generation. | |
